<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777073</url>
  </required_header>
  <id_info>
    <org_study_id>1974</org_study_id>
    <nct_id>NCT02777073</nct_id>
  </id_info>
  <brief_title>Effects of Single Doses of Liraglutide and Dapagliflozin on Hyperglycemia and Ketogenesis in Type 1 Diabetes</brief_title>
  <acronym>1974</acronym>
  <official_title>Effects of Single Doses of Liraglutide and Dapagliflozin on Hyperglycemia and Ketogenesis in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To compare levels of ketone bodies (beta-hydroxybutyrate and acetoacetate) in plasma and
           urine following a single dose treatment of either liraglutide 1.8mg,dapagliflozin 10mg
           or placebo in insulinopenic state.

        2. To compare plasma levels of free fatty acid, glucagon, hs-CRP, Il-6 and IL-1 before and
           after administration of liraglutide/Dapagliflozin/placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic ketoacidosis is an important cause of mortality and morbidity in type 1 patients.
      The decreased ratio of insulin to glucagon in insulin deficient subjects promotes
      ketogenesis. In patients with type 1 diabetes, the suppressive effect of hyperglycemia and
      the paracrine inhibitory effect of insulin and GABA from the β cell on α cell are absent.
      Thus, plasma glucagon concentrations are elevated and in combination with insulin deficiency,
      lead to lipolysis, increased plasma FFA concentrations and an increased fatty acid supply to
      the liver. Thus, both fatty acid oxidation and ketogenesis are enhanced.

      Our recent work has shown that liraglutide, a GLP 1 agonist, improves glycemic control and
      reduces glycemic excursions in patients with type 1 diabetes within a few days of the
      initiation of treatment.

      With this background, the investigators hypothesize that suppression of glucagon with
      liraglutide in patients with type 1 diabetes may protect them from lipolysis, increased
      bio-availability of FFAs, ketogenesis and ketoacidosis. On the other hand, addition of SGLT 2
      inhibitor can shift these biochemical changes to other direction thus increasing ketogenesis
      /ketoacidosis.

      It is essential to investigate this area further as there are no prior studies that have
      investigated the acute effects of liraglutide/Dapagliflozin on FFAs or ketogenesis. This
      study will be the first randomized controlled prospective study investigating the effect of
      liraglutide/dapagliflozin on ketogenesis. Also, it would be important to measure the
      mediators of inflammation at the same time to investigate whether there is a concomitant
      changes of inflammatory factors in parallel with the lipolysis and ketogenesis.

      After the screening visit, subjects who meet the inclusion and exclusion criteria will be
      randomized to receive a single dose of either liraglutide, dapagliflozin or placebo and will
      be monitored for a total of 8 hours. The same patient (as described in 8.3, cross over
      study), will get the other 2 treatments in random order in the following 2 visits (one week
      apart) for a total participation of 2 weeks+1 day.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference in ketone bodies formation after single dose of liraglutide and dapagliflozin</measure>
    <time_frame>8 hours</time_frame>
    <description>To compare levels of ketone bodies (beta-hydroxybutyrate and acetoacetate) in plasma and urine following a single dose treatment of either liraglutide 1.8mg,dapagliflozin 10mg or placebo in insulinopenic state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>effect of liraglutide and dapagliflozin on glucagon concentrations</measure>
    <time_frame>8 hours</time_frame>
    <description>This secondary endpoint compares the area under the curve for glucagon over a period of 8 hours following liraglutide and dapagliflozin compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of liraglutide and dapagliflozin on Free Fatty Acid</measure>
    <time_frame>8 hours</time_frame>
    <description>This secondary endpoint compares the area under the curve for Free Fatty Acid over a period of 8 hours following liraglutide and dapagliflozin compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of liraglutide and dapagliflozin on C-Reactive Protein</measure>
    <time_frame>8 Hours</time_frame>
    <description>This secondary endpoint compares the area under the curve for C-reactive protein over a period of 8 hours following liraglutide and dapagliflozin compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of liraglutide and dapagliflozin on IL-6 and IL1-b</measure>
    <time_frame>8 hours</time_frame>
    <description>This secondary endpoint compares the area under the curve for IL-6 and IL1-b over a period of 8 hours following liraglutide and dapagliflozin compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>liraglutide 1.8 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose of Victoza ( liraglutide) 1.8 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dapagliflozin 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of Farxiga ( dapagliflozin) 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Farxiga</intervention_name>
    <description>Single dose of dapagliflozin</description>
    <arm_group_label>dapagliflozin 10</arm_group_label>
    <other_name>dapagliflozin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Victoza</intervention_name>
    <description>Single dose of Liraglutide</description>
    <arm_group_label>liraglutide 1.8 mg</arm_group_label>
    <other_name>Liraglutide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of generic placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 1 Diabetes on continuous subcutaneous insulin infusion (CSII, also known as
             insulin pump).

          2. Undetectable c peptide (c-peptide &lt; 0.1 ng/ml).

          3. HbA1c of less than or equal to 8.5%.

          4. Age 18-75 inclusive

        Exclusion Criteria:

          1. Type 1 diabetes for less than 12 months

          2. Coronary event/ procedure (MI, Unstable angina, CABG, PCI) in the last four weeks

          3. Hepatic disease (Transaminase &gt; 3 times normal) or Cirrhosis

          4. Renal impairment (serum eGFR &lt;30ml/min/1.73m2)

          5. HIV or Hepatitis B or C positive status

          6. History of pancreatitis, i.e., history of gallstones, alcohol abuse and
             hypertriglyceridemia

          7. Pregnancy

          8. Inability to give informed consent

          9. History of Gastroparesis

         10. Personal or Family History of medullary thyroid carcinoma or MEN 2 syndrome

         11. Alcoholism

         12. Hypertriglyceridemia (&gt;500 mg/dl).

         13. Those with history of bladder cancer , diabetic ketoacidosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ECMC Ambulatory Center, 3rd Floor</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>May 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Paresh Dandona</investigator_full_name>
    <investigator_title>Distinguished Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetic ketoacidosis</keyword>
  <keyword>Insulin</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>glucose (sugar) control</keyword>
  <keyword>SGLT-2 inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

